N-Acylated sulfonamide congeners of fosmidomycin lack any inhibitory activity against DXR by Gadakh, Bharat et al.
N-acylated sulfonamide congeners of fosmidomycin lack any inhibitory 
activity against DXR.  
Bharat Gadakh1, Jenny Pouyez2, Johan Wouters2, Akkaladevi Venkatesham1, Paul Cos3, 
Arthur Van Aerschot1 
1 Medicinal Chemistry, Rega Institute for Medical Research, KU Leuven, 
Minderbroedersstraat 10, 3000 Leuven, Belgium; 2 Department of Chemistry, University of 
Namur, Rue de Bruxelles 61, Namur B-5000, Belgium; 3 Laboratory of Microbiology, 
Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, 2610 
Wilrijk, Belgium.  
 
Abstract 
The antibiotic fosmidomycin (3) is an inhibitor of the non-mevalonate pathway for isoprenoid 
biosynthesis. Four analogues in which an acylated sulfonamide group is substituting for its 
phosphonate moiety have been synthesized in a fruitless effort to preserve one negative charge 
in order to increase the accompanying affinity for 1-deoxy-D-xylulose 5-phosphate 
reductoisomerase (DXR), the fosmidomycin target enzyme. 
 
In view of the ease with which bacterial resistance against various inhibitors spreads, the 
development of new antibiotics remains of prime importance. Treatment of malaria likewise 
suffers from resistance to all available therapeutics, and the search for new inhibitors and new 
targets therefore should be the concern of many medicinal chemists. The non-mevalonate 
pathway for isoprenoid biosynthesis, not being found in higher eukaryotes,1 therefore represents 
an interesting target for drug development. The most studied enzyme in this pathway is the 1-
deoxy-D-xylulose 5-phosphate (DOXP, 1, Figure 1) reductoisomerase (DXR, also abbreviated 
IspC), catalyzing the conversion of the xylulose derivative 1 into 2-C-methyl-D-erythritol 3-
phosphate (MEP, 2)2-4 and is a clinically validated target. Herein the natural antibiotic 
fosmidomycin (3a) and its acetyl congener (3b) have been known for a long time5 and forms 
the hallmark for inhibition of DXR, but its use for treatment of malaria is hampered by its 
unfavorable pharmacokinetic properties.6,7 In view of highly needed possible treatments for 
malaria or for tuberculosis, a multitude of analogues have been synthesized over the past 20 
years as recently very nicely reviewed by Masini and Hirsch.8 Both, the sulfone and the 
sulfonamide carrying various alkyl or arylalkyl residues of different length in the past have 
been evaluated as possible isosters for the phosphonate moiety.9 While it was envisioned that 
the absence of a negative charge could have facilitated the uptake, unfortunately no significant 
inhibitory activity was noted. This indicates that a negative charge at the phosphonate moiety 
position is mandatory for enzymatic inhibition. 
While the sulfone and alkylsulfonamide analogues (deliberately) lacked a negative charge, it is 
well-known that the NH moiety of acylated sulfonamides with their enhanced imide-like 
structure carries a pKa well beneath the physiological pH. Indeed, two recent reports herein 
refer to a pKa of around 2.0 or 2.5 for an aliphatic acyl sulfonamide.10,11 Aminoacylated 
sulfonamide nucleoside analogues therefore are common knowledge isosters of the 
aminoacylated adenylate intermediates formed by the respective tRNA synthetases, in which 
the deprotonated amide is mimicking the remaining negative charge of the natural adenylate 
intermediate.12 We therefore decided to corroborate this hypothesis in synthesizing the 
fosmidomycin analogues 4a-d (Figure 1) and evaluating their inhibitory properties on E. coli 
DXR. We hoped this way to at least partially restore the inhibitory activity in analogy with 
which was noted for phosphonate monoesters9 and the expected inhibitory activity could then 
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Figure 1. Inhibition of E. coli DXR by fosmidomycin (top) and the envisaged acylated 



































a: R = CH3- b: R = PhCH2-
c: R = Ph- d: R = PhCH2CH2-  
 
Scheme 1: reagent and conditions: (a) (i) NaI, CH3CN, 10 min, rt (ii) TMSCl, rt, 15 min, (iii) 
NH2OBn, rt, 10 min (iv) NaBH3CN, TFA, rt, 1h (v) Et3N, AcCl, rt, 30 min (one pot, 60%); (b) 
BnSNa, THF, -78oC, 1h (90%); (c) ACN:AcOH:H2O, DCDMH, 0oC to 5oC, 1 h; add to aq. 
ammonia solution (25%w/v), 0oC to 20oC, 1 h (96%); (d) acyl chloride, TEA, DMAP, dry 
DMF, dry DCM, 0oC to rt (9a: 90%; 9b: 39%; 9c: 51%; 9d: 61%); (e) Pd/C, methanol, H2 
atmosphere, 1-4 h (4a: 46%; 4b: 46%; 4c: 50%; 4d: 42%). 
 
Synthesis of the key intermediate 6 has been documented before and starts from acroleine (5) 
affording 60% of the iodinated precursor in a convenient one-pot reaction.13 Conversion to the 
non-alkylated sulfonamide did not prove straightforward, and the iodide was smoothly 
converted to the benzyl thioether 7, which upon treatment with 2,4-dichloro-5,5-
dimethylhydantoin (DCDMH) was oxidatively chlorinated and in situ converted to the 
sulfonamide derivative 8 with aqueous ammonia in 96% yield.14 This little known methodology 
using DCDMH indeed proved to be a mild and efficient procedure for the direct conversion of 
sulfur compounds to the corresponding arenesulfonyl chlorides in excellent yields. Acylation 
afforded the compounds 9a-d which upon debenzylation gave the target compounds 4a-d in 
very moderate yields.15  
 
The importance of a negative charge (the phosphonate part) has been evaluated in 2008 by 
Perruchon et al.9 and sulfonamide analogues lacking this charge proved inactive.  Acylation of 
the sulfonamide renders the nitrogen more acidic and should result in a negative charge at 
physiological pH. These efforts therefore constitute a first attempt in trying to improve the 
affinity for the enzyme. If this hypothesis is borne out, we could start developing a new series 
of compounds. The new fosmidomycin mimics therefore were evaluated for their inhibitory 
effects on the E. coli DXR enzyme using a spectrophotometric assay monitoring the substrate 
dependent oxidation of NAPDH. Unfortunately, even in presence of 100  concentrations of 
4a-d, the residual enzymatic activity remained at or close to 100%, highlighting the absence of 
inhibitory effects of the acylated sulfonamides for the target enzyme (supplementary file).  
Besides generating a negative charge, the choice for synthesizing 4b was inspired by the activity 
as reported for the phenylethyl phosphonate ester9, where apparently the phenyl moiety can be 
accommodated in the active site and increases the inhibitor activity. According to our molecular 
modeling the acyl moiety of 4b indeed can be placed in a larger hydrophobic pocket as was 
expected for the larger phosphonate esters9 and as shown for alpha-phenyl substituted 
analogues of fosmidomycin.10 In view of the absence of inhibitory activity for 4a-b on DXR, 
the congeners 4c and 4d were synthesized, as both side chains likewise in silico can be 
accommodated in the active site as shown in the supplementary file. Based on docking (steric 
effects), there is thus no obvious reason why the compounds should not be active. Hence, except 
for a much more delocalized charge, a rationale for the lack of affinity for the compounds 4b-
d for the target enzyme is missing, but discourages therefore further exploration of this scaffold. 
Adding to all previous efforts, it is clear now there is little room for substituting the 
fosmidomycin phosphonate moiety. Recent efforts to alter the chelating moiety of the lead 
compound likewise proved deleterious to the inhibitory activity.10   
The newly synthesized compounds 4a and 4b in addition were subjected to a broad screening 
panel including Trypanosoma brucei, Trypanosoma cruzi, Leishmania infantum, Plasmodium 
falciparum K1, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, 
Trichophyton rubrum, Candida albicans, Aspergillus fumigatus and MRC-5 cells. However, no 
antimicrobial activity nor any cellular toxicity could be noted at the highest test concentration 
of 64 µM.16  
In conclusion, it has been corroborated that acylation of sulfonamide mimics of the 
fosmidomycin phoshonate part is not able to restore the inhibitory effect on E. coli DXR, nor 
are the new compounds endowed with any antibacterial or antiparasitic activity.   
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